# Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents

> **NCT04992260** · PHASE3 · COMPLETED · sponsor: **Sinovac Research and Development Co., Ltd.** · enrollment: 11349 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Inactivated COVID-19 Vaccine
- **BIOLOGICAL:** Controlled vaccine

## Key facts

- **NCT ID:** NCT04992260
- **Lead sponsor:** Sinovac Research and Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 11349 (ACTUAL)
- **Last updated:** 2023-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04992260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04992260, "Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04992260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*